用阿扎胞苷治疗的伴有骨髓纤维化的骨髓增生异常综合征（MDS-F）患者的血液学改善情况。
Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine.
作者信息
Okamura Daisuke, Matsuda Akira, Ishikawa Maho, Maeda Tomoya, Tanae Ken, Kohri Mika, Takahashi Naoki, Kawai Nobutaka, Asou Norio, Bessho Masami
机构信息
Department of Hemato-Oncology, Comprehensive Cancer Center, Saitama International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.
出版信息
Leuk Res Rep. 2014 Apr 16;3(1):24-7. doi: 10.1016/j.lrr.2014.03.002. eCollection 2014.
Abstract
Myelodysplastic syndromes with myelofibrosis (MDS-F) is a poor prognostic hematopoietic disorder. Azacitidine was shown to prolong survival of high-risk MDS patients. However, the effects of azacitidine on MDS-F have yet to be elucidated. Azacitidine was administered to a 74-year-old man with MDS-F at a dose of 75 mg/m(2)/daily subcutaneously for 7 days every 28 days. Hematologic improvements were observed according to the International Working Group 2006 criteria after 8 cycles of the azacitidine treatment, and complete remission was achieved after 14 cycles. The grade of myelofibrosis was also improved. The therapeutic activity of azacitidine was confirmed in our MDS-F patient.
摘要
伴有骨髓纤维化的骨髓增生异常综合征（MDS-F）是一种预后不良的造血系统疾病。阿扎胞苷已被证明可延长高危MDS患者的生存期。然而，阿扎胞苷对MDS-F的影响尚未阐明。一名74岁的MDS-F男性患者接受阿扎胞苷治疗，剂量为75mg/m²/天，皮下注射，每28天持续7天。根据国际工作组2006年标准，在阿扎胞苷治疗8个周期后观察到血液学改善，14个周期后实现完全缓解。骨髓纤维化程度也有所改善。在我们的MDS-F患者中证实了阿扎胞苷的治疗活性。
相似文献
1
Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine.用阿扎胞苷治疗的伴有骨髓纤维化的骨髓增生异常综合征（MDS-F）患者的血液学改善情况。
Leuk Res Rep. 2014 Apr 16;3(1):24-7. doi: 10.1016/j.lrr.2014.03.002. eCollection 2014.
2
Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.分子学确诊的阿扎胞苷治疗骨髓增生异常综合征病例的细胞遗传学缓解
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017 Dec 1;38(3):157-162. doi: 10.2478/prilozi-2018-0017.
3
[Myelodysplastic syndrome with myelofibrosis in which azacitidine therapy was effective and cord blood transplantation was carried out].[阿扎胞苷治疗有效的伴有骨髓纤维化的骨髓增生异常综合征并进行了脐血移植]
Rinsho Ketsueki. 2017;58(6):601-606. doi: 10.11406/rinketsu.58.601.
4
Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.阿扎胞苷治疗低危骨髓增生异常综合征：一项意大利患者登记项目中 74 例患者的回顾性研究。
Cancer. 2010 Mar 15;116(6):1485-94. doi: 10.1002/cncr.24894.
5
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.高危骨髓增生异常综合征中地西他滨治疗经验的更新及与预后相关的预后因素分析
Cancer. 2007 Jan 15;109(2):265-73. doi: 10.1002/cncr.22376.
6
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.阿扎胞苷-来那度胺（ViLen）联合方案在高危骨髓增生异常综合征（MDS）-ViLen-01方案中产生了高缓解率。
Ann Hematol. 2016 Oct;95(11):1811-8. doi: 10.1007/s00277-016-2776-x. Epub 2016 Aug 22.
7
A limited number of 5-azacitidine cycles can be effective treatment in MDS.有限数量的5-氮杂胞苷疗程可作为骨髓增生异常综合征的有效治疗方法。
Ann Hematol. 2009 Mar;88(3):213-9. doi: 10.1007/s00277-008-0583-8. Epub 2008 Aug 12.
8
Immunemodulatory Effects of 5-Azacitidin Through Expansion of Functional Regulatory T Cells on Paraneoplastic Inflammation Associated With Myelodysplastic Syndromes: A Case Report.5-氮杂胞苷通过扩增功能性调节性T细胞对骨髓增生异常综合征相关副肿瘤性炎症的免疫调节作用：一例报告
Front Oncol. 2018 Jun 5;8:204. doi: 10.3389/fonc.2018.00204. eCollection 2018.
9
5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.5-氮杂胞苷在临床试验之外治疗年龄>65 岁骨髓增生异常综合征患者的疗效和安全性。
Leuk Lymphoma. 2012 Aug;53(8):1558-60. doi: 10.3109/10428194.2012.660632. Epub 2012 Feb 21.
10
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.低剂量地西他滨与低剂量阿扎胞苷治疗低危骨髓增生异常综合征和骨髓增生异常综合征/骨髓增殖性肿瘤的随机2期研究
Blood. 2017 Sep 28;130(13):1514-1522. doi: 10.1182/blood-2017-06-788497. Epub 2017 Aug 3.
引用本文的文献
1
Prognostic impact of peripheral blood mRNA expression levels in response to azacytidine in MDS: A single-centre analysis.骨髓增生异常综合征中阿扎胞苷治疗外周血mRNA表达水平的预后影响：单中心分析
Leuk Res Rep. 2020 Dec 8;15:100231. doi: 10.1016/j.lrr.2020.100231. eCollection 2021.
2
Physiological and pathological implications of 5-hydroxymethylcytosine in diseases.5-羟甲基胞嘧啶在疾病中的生理和病理意义
Oncotarget. 2016 Jul 26;7(30):48813-48831. doi: 10.18632/oncotarget.9281.
本文引用的文献
1
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.COMFORT-II 研究的 3 年疗效、安全性和生存结果，该研究是一项比较芦可替尼与骨髓纤维化最佳可用疗法的 3 期研究。
Blood. 2013 Dec 12;122(25):4047-53. doi: 10.1182/blood-2013-02-485888. Epub 2013 Oct 30.
2
Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.异基因造血干细胞移植治疗骨髓纤维化伴骨髓增生异常综合征。
Haematologica. 2011 Feb;96(2):291-7. doi: 10.3324/haematol.2010.031229. Epub 2010 Oct 22.
3
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.在 282 例接受阿扎胞苷治疗的高危骨髓增生异常综合征患者中，预测反应和总生存的预后因素。
Blood. 2011 Jan 13;117(2):403-11. doi: 10.1182/blood-2010-06-289280. Epub 2010 Oct 12.
4
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.泊马度胺在治疗与骨髓纤维化相关的贫血方面具有活性。
J Clin Oncol. 2009 Sep 20;27(27):4563-9. doi: 10.1200/JCO.2008.21.7356. Epub 2009 Aug 3.
5
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.阿扎胞苷与传统治疗方案治疗高危骨髓增生异常综合征的疗效比较：一项随机、开放标签的III期研究。
Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21.
6
Decitabine is an effective treatment of idiopathic myelofibrosis.地西他滨是治疗原发性骨髓纤维化的一种有效疗法。
Br J Haematol. 2009 Apr;145(1):131-2. doi: 10.1111/j.1365-2141.2008.07541.x. Epub 2008 Dec 26.
7
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.一项针对原发性和原发性血小板增多症/真性红细胞增多症骨髓纤维化患者的5-氮杂胞苷II期研究。
Leukemia. 2008 May;22(5):965-70. doi: 10.1038/leu.2008.91. Epub 2008 Apr 3.
8
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.来那度胺治疗骨髓化生的骨髓纤维化。
Blood. 2006 Aug 15;108(4):1158-64. doi: 10.1182/blood-2006-02-004572. Epub 2006 Apr 11.
9
Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.慢性骨髓增殖性疾病患者血清白细胞介素（IL）-1、IL-2、可溶性IL-2受体（sIL-2Ra）、IL-6和血小板生成素水平
Br J Haematol. 2005 Sep;130(5):709-15. doi: 10.1111/j.1365-2141.2005.05674.x.
10
Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.低剂量沙利度胺改善骨髓化生的骨髓纤维化中的血细胞减少和脾肿大：一项II期试验。
J Clin Oncol. 2004 Feb 1;22(3):424-31. doi: 10.1200/JCO.2004.08.160.
Zotero 插件